Article
Multidisciplinary Sciences
I-M Launonen, N. Lyytikainen, J. Casado, E. A. Anttila, A. Szabo, U-M Haltia, C. A. Jacobson, J. R. Lin, Z. Maliga, B. E. Howitt, K. C. Strickland, S. Santagata, K. Elias, A. D. D'Andrea, P. A. Konstantinopoulos, P. K. Sorger, A. Farkkila
Summary: In this study, the authors used highly multiplexed imaging to analyze the immune microenvironment of high-grade serous ovarian cancers (HGSOC) and identified phenotypic characteristics and spatial interactions associated with BRCA1/2 gene mutations. These findings have important implications for improving immunotherapeutic strategies and patient stratification.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Qian Hao, Jiajia Li, Qinghua Zhang, Fei Xu, Bangxiang Xie, Hua Lu, Xiaohua Wu, Xiang Zhou
Summary: This study using single-cell transcriptomics analysis of HGSOC samples reveals new molecular features and potential therapeutic targets, which could advance the understanding and treatment of the disease.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Paula Punzon-Jimenez, Victor Lago, Santiago Domingo, Carlos Simon, Aymara Mas
Summary: High-grade serous ovarian carcinoma (HGSOC) is the most common form of epithelial ovarian carcinoma, and its early diagnosis still relies on traditional methods. Research on its etiopathogenesis provides new insights for finding early detection methods.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yicheng Wang, Haoling Xie, Xiaohong Chang, Wenqi Hu, Mengyao Li, Yi Li, Huiping Liu, Hongyan Cheng, Shang Wang, Ling Zhou, Danhua Shen, Sha Dou, Ruiqiong Ma, Yunuo Mao, Honglan Zhu, Xiaobo Zhang, Yuxuan Zheng, Xue Ye, Lu Wen, Kehkooi Kee, Heng Cui, Fuchou Tang
Summary: This study provides insights into the molecular characteristics of high-grade serous ovarian cancer through integrated analysis of multiomic changes and epigenetic regulation. It reveals the upregulation of interferon signaling and metallothioneins, which are influenced by demethylation and hypomethylation. The study also suggests the potential preexistence of metastatic cells in the subclones of primary tumors.
Review
Oncology
Lana E. Kandalaft, Denarda Dangaj Laniti, George Coukos
Summary: This review proposes a classification system based on immunophenotypes to explain the failures of existing immunotherapies in high-grade serous ovarian cancers, and suggests that rational therapeutic approaches tailored to each immunophenotype might meet with improved success.
NATURE REVIEWS CANCER
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Takayuki Mori, Hiroki Kato, Masaya Kawaguchi, Yuichiro Hatano, Takuma Ishihara, Yoshifumi Noda, Fuminori Hyodo, Masayuki Matsuo, Tatsuro Furui, Ken-ichirou Morishige
Summary: This study aimed to evaluate the MRI findings of different types of endometrial cancer. Serous carcinoma (SC) showed heterogeneous signal with peritoneal dissemination and abnormal ascites, while clear cell carcinoma (CCC) exhibited larger tumor size, higher ADC values, infiltrative growth pattern, heterogeneous signal, and abnormal ascites.
EUROPEAN RADIOLOGY
(2022)
Article
Medicine, Research & Experimental
Yuanzhi Chen, Zhicheng He, Shuting Yang, Cheng Chen, Wenyong Xiong, Yingying He, Shubai Liu
Summary: In this study, it was found that RUNX1 plays a crucial role in the development of high-grade serous ovarian cancer (HGSOC). It regulates apoptosis and EMT function, impacting the physiological function of ovarian cancer cells. Down-regulation of RUNX1 increases sensitivity to drug therapy for ovarian cancer. This research has significant implications for the diagnosis and treatment of HGSOC patients.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Chiho Miyagawa, Hidekatsu Nakai, Tomoyuki Otani, Ryusuke Murakami, Shiki Takamura, Hisamitsu Takaya, Kosuke Murakami, Masaki Mandai, Noriomi Matsumura
Summary: We modified the histopathologic subtyping algorithm to achieve high interobserver agreement in whole slide imaging and characterized the tumor biology of MT type for treatment individualization. The results showed that MT type had a worse prognosis and genes related to angiogenesis and immune response were highly expressed in the MT type. The findings of this study may be useful for treatment individualization of HGSOC, including angiogenesis inhibitors and immunotherapy.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)
Article
Genetics & Heredity
Dale W. Garsed, Ahwan Pandey, Sian Fereday, Catherine J. Kennedy, Kazuaki Takahashi, Kathryn Alsop, Phineas T. Hamilton, Joy Hendley, Yoke-Eng Chiew, Nadia Traficante, Pamela Provan, Dinuka Ariyaratne, George Au-Yeung, Nicholas W. Bateman, Leanne Bowes, Alison Brand, Elizabeth L. Christie, Julie M. Cunningham, Michael Friedlander, Bronwyn Grout, Paul Harnett, Jillian Hung, Bryan McCauley, Orla McNally, Anna M. Piskorz, Flurina A. M. Saner, Robert A. Vierkant, Chen Wang, Stacey J. Winham, Paul D. P. Pharoah, James D. Brenton, Thomas P. Conrads, George L. Maxwell, Susan J. Ramus, Celeste Leigh Pearce, Malcolm C. Pike, Brad H. Nelson, Ellen L. Goode, Anna DeFazio, David D. L. Bowtell
Summary: This study analyzed the genomic, transcriptomic, and methylomic profiles of patients with advanced-stage HGSC who survived more than 10 years after diagnosis. Long-term survivors had more alterations in DNA repair genes and higher neoantigen load. Patients were clustered into survival groups based on genomic and immune cell signatures, including different subsets of patients with BRCA1 alterations. Specific combinations of genetic and immune factors contribute to long-term survival in HGSC.
Article
Oncology
Robert L. Hollis, Alison M. Meynert, Caroline O. Michie, Tzyvia Rye, Michael Churchman, Amelia Hallas-Potts, Ian Croy, W. Glenn McCluggage, Alistair R. W. Williams, Clare Bartos, Yasushi Iida, Aikou Okamoto, Brian Dougherty, J. Carl Barrett, Ruth March, Athena Matakidou, Patricia Roxburgh, Colin A. Semple, D. Paul Harkin, Richard Kennedy, C. Simon Herrington, Charlie Gourley
Summary: This study characterized the molecular landscape of HGSOC and identified specific molecular events associated with clinical prognosis and treatment response. The results showed that patients with BRCA2 gene mutations and EMSY gene overexpression had longer survival and higher chemotherapy response rate. Patients with CCNE1 gene gain had lower proportion of stage IV cases and shorter survival, but no significant difference in treatment response.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Akira Yokoi, Mayu Ukai, Takao Yasui, Yasuhide Inokuma, Kim Hyeon-Deuk, Juntaro Matsuzaki, Kosuke Yoshida, Masami Kitagawa, Kunanon Chattrairat, Mikiko Iida, Taisuke Shimada, Yumehiro Manabe, I-Ya Chang, Eri Asano-Inami, Yoshihiro Koya, Akihiro Nawa, Kae Nakamura, Tohru Kiyono, Tomoyasu Kato, Akihiko Hirakawa, Yusuke Yoshioka, Takahiro Ochiya, Takeshi Hasegawa, Yoshinobu Baba, Yusuke Yamamoto, Hiroaki Kajiyama
Summary: Cancer cell-derived extracellular vesicles (EVs) could be potential targets for disease biomarkers due to their unique protein profiles. Analysis of small EVs (sEVs) and medium/large EVs (m/lEVs) revealed that both subtypes had distinct proteomic characteristics. Specific sEV proteins (FRa, Claudin-3, and TACSTD2) for high-grade serous ovarian carcinoma (HGSOC) were identified, while no candidates were found for m/lEVs. Additionally, a microfluidic device using polyketone-coated nanowires (pNWs) was developed for efficient sEV isolation and showed specific detectability in cancer patients and predicted clinical status.
Article
Cell Biology
Tova M. Bergsten, Sarah E. Levy, Katherine E. Zink, Hannah J. Lusk, Melissa R. Pergande, Stephanie M. Cologna, Joanna E. Burdette, Laura M. Sanchez
Summary: This study discovered that a secreted protein called SPARC, produced by tumorigenic fallopian tube epithelial cells, enhances the release of norepinephrine (NE) from the ovary, influencing the primary metastasis of high grade serous ovarian cancer (HGSOC).
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Immunology
Yingqing Deng, Yuan Tan, Dongmei Zhou, Youhuang Bai, Ting Cao, Caizhou Zhong, Weilai Huang, Yuhua Ou, Linlang Guo, Qianqian Liu, Deling Yin, Lipai Chen, Xiping Luo, Deqiang Sun, Xiujie Sheng
Summary: This study investigated the molecular mechanism and biology of metastatic high-grade serous ovarian cancer (HG_M) through single-cell RNA sequencing analysis. The findings revealed amplified genes in metastatic tumors, malignant cells exhibiting features of epithelial-mesenchymal transition (EMT) associated with poor prognosis, and enrichment of cancer-associated fibroblasts with EMT-program involved in angiogenesis and immune regulation. Compared to another subtype, high-grade serous ovarian cancer showed higher T cell infiltration.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Wenying Chen, Hanyuan Liu, Xinya Huang, Lili Qian, Liang Chen, Yonggang Zhou, Yi Liu, Yujie Liu, Yingying Wang, Tianjiao Zhang, Youyang Zhou, Jingwen Fang, Jiaxuan Yang, Fang Ni, Chuang Guo, Ying Zhou
Summary: High-grade serous ovarian cancer (HGSOC) is characterized by different tumor microenvironments (TME) in pre-menopausal and post-menopausal patients, exhibiting variations in cell proportions and immune pathways.
Article
Medicine, General & Internal
Katelyn F. Handley, Travis T. Sims, Nicholas W. Bateman, Deanna Glassman, Katherine Foster, Sanghoon Lee, Jun Yao, Hui Yao, Bryan M. Fellman, Jinsong Liu, Zhen Lu, Kelly A. Conrads, Brian L. Hood, Waleed Barakat, Li Zhao, Jianhua Zhang, Shannon N. Westin, Joseph Celestino, Kelly M. Rangel, Sunil Badal, Igor Pereira, Prahlad T. Ram, George L. Maxwell, Livia S. Eberlin, P. Andrew Futreal, Robert C. Bast, Nicole D. Fleming, Thomas P. Conrads, Anil K. Sood
Summary: This study identified two novel, gross morphologic subtypes of HGSOC, each with unique clinical features and molecular signatures. These findings may have important implications for triaging patients to surgery or chemotherapy, evaluating outcomes, and developing tailored therapeutic strategies.